Pharmacogenetics in Primary Headache Disorders

doi:10.3389/fphar.2021.820214

Review

. 2022 Feb 10:12:820214.

doi: 10.3389/fphar.2021.820214. eCollection 2021.

Pharmacogenetics in Primary Headache Disorders

Irina I Belyaeva^{1

2}, Anna G Subbotina^{1

2}, Ivan I Eremenko^{1

2}, Vadim V Tarasov^{2

3}, Vladimir N Chubarev², Helgi B Schiöth^{1

3}, Jessica Mwinyi¹

Affiliations

¹ Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden.
² Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
³ Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.

PMID: 35222013
PMCID: PMC8866828
DOI: 10.3389/fphar.2021.820214

Review

Pharmacogenetics in Primary Headache Disorders

Irina I Belyaeva et al. Front Pharmacol. 2022.

. 2022 Feb 10:12:820214.

doi: 10.3389/fphar.2021.820214. eCollection 2021.

Authors

Irina I Belyaeva^{1

2}, Anna G Subbotina^{1

2}, Ivan I Eremenko^{1

2}, Vadim V Tarasov^{2

3}, Vladimir N Chubarev², Helgi B Schiöth^{1

3}, Jessica Mwinyi¹

Affiliations

¹ Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden.
² Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.
³ Institute of Translational Medicine and Biotechnology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.

PMID: 35222013
PMCID: PMC8866828
DOI: 10.3389/fphar.2021.820214

Abstract

Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin-angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.

Keywords: cluster headache (CH); drug treatment; migraine; pharmacodynamics; pharmacogenetics; pharmacokinetics; tension-type headache.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Cited by

Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks.
Rubino E, Marcinnò A, Grassini A, Piella EM, Ferrandes F, Roveta F, Boschi S, Cermelli A, Gallone S, Savi L, Rainero I. Rubino E, et al. Int J Mol Sci. 2022 Dec 30;24(1):657. doi: 10.3390/ijms24010657. Int J Mol Sci. 2022. PMID: 36614097 Free PMC article.
Relationship Between Changes in Cranio-Cervical Extensor Muscles and Quality of Life: A Single-Center Study of 15 Patients with Chronic Tension-Type Headache.
Min X, Huo Y, Sun N, Zhi H, Li H, Zhang S, Cui W, Guo Y, Wu H. Min X, et al. Med Sci Monit. 2023 Feb 13;29:e938574. doi: 10.12659/MSM.938574. Med Sci Monit. 2023. PMID: 36775942 Free PMC article.
Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities.
Burish MJ, Guirguis AB, Schindler EAD. Burish MJ, et al. Curr Neurol Neurosci Rep. 2024 Sep;24(9):439-452. doi: 10.1007/s11910-024-01362-x. Epub 2024 Jul 17. Curr Neurol Neurosci Rep. 2024. PMID: 39017830 Review.
Primary Dengue and Long-Term Health Status in Madeira Island, Portugal: A Retrospective Questionnaire-Based Study.
Henriques P, Caldeira-Araújo H, Brazão MDL, Abreu AM, Vigário AM, Rosa A. Henriques P, et al. Am J Trop Med Hyg. 2024 Jul 2;111(2):403-411. doi: 10.4269/ajtmh.23-0502. Print 2024 Aug 7. Am J Trop Med Hyg. 2024. PMID: 38955194 Free PMC article.
Genetics of migraine: where are we now?
Grangeon L, Lange KS, Waliszewska-Prosół M, Onan D, Marschollek K, Wiels W, Mikulenka P, Farham F, Gollion C, Ducros A; European Headache Federation School of Advanced Studies (EHF-SAS). Grangeon L, et al. J Headache Pain. 2023 Feb 20;24(1):12. doi: 10.1186/s10194-023-01547-8. J Headache Pain. 2023. PMID: 36800925 Free PMC article. Review.

See all "Cited by" articles

References

1. Affatato O., Moulin T. C., Pisanu C., Babasieva V. S., Russo M., Aydinlar E. I., et al. (2021). High Efficacy of onabotulinumtoxinA Treatment in Patients with Comorbid Migraine and Depression: a Meta-Analysis. J. Transl Med. 19 (1), 133. 10.1186/s12967-021-02801-w - DOI - PMC - PubMed
1. Afridi S. K., Shields K. G., Bhola R., Goadsby P. J. (2006). Greater Occipital Nerve Injection in Primary Headache Syndromes-Pprolonged Effects from a Single Injection. Pain 122 (1-2), 126–129. 10.1016/j.pain.2006.01.016 - DOI - PubMed
1. Aggarwal M., Puri V., Puri S. (2012). Serotonin and CGRP in Migraine. Ann. Neurosci. 19 (2), 88–94. 10.5214/ans.0972.7531.12190210 - DOI - PMC - PubMed
1. Agius A. M., Muscat R. (2019). Chronic Tension-type Facial Pain-A Pilot Study on HTTLPR Genetic Polymorphisms. Rhinology Online 2 (2), 125–133. 10.4193/rhinol/19.036 - DOI
1. Ahn A. H., Basbaum A. I. (2005). Where Do Triptans Act in the Treatment of Migraine. Pain 115 (1-2), 1–4. 10.1016/j.pain.2005.03.008 - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Molecular Biology Databases
- Pharmacogenomics Knowledge Base

[1] Affatato O., Moulin T. C., Pisanu C., Babasieva V. S., Russo M., Aydinlar E. I., et al. (2021). High Efficacy of onabotulinumtoxinA Treatment in Patients with Comorbid Migraine and Depression: a Meta-Analysis. J. Transl Med. 19 (1), 133. 10.1186/s12967-021-02801-w - DOI - PMC - PubMed

[2] Affatato O., Moulin T. C., Pisanu C., Babasieva V. S., Russo M., Aydinlar E. I., et al. (2021). High Efficacy of onabotulinumtoxinA Treatment in Patients with Comorbid Migraine and Depression: a Meta-Analysis. J. Transl Med. 19 (1), 133. 10.1186/s12967-021-02801-w - DOI - PMC - PubMed

[3] Afridi S. K., Shields K. G., Bhola R., Goadsby P. J. (2006). Greater Occipital Nerve Injection in Primary Headache Syndromes-Pprolonged Effects from a Single Injection. Pain 122 (1-2), 126–129. 10.1016/j.pain.2006.01.016 - DOI - PubMed

[4] Afridi S. K., Shields K. G., Bhola R., Goadsby P. J. (2006). Greater Occipital Nerve Injection in Primary Headache Syndromes-Pprolonged Effects from a Single Injection. Pain 122 (1-2), 126–129. 10.1016/j.pain.2006.01.016 - DOI - PubMed

[5] Aggarwal M., Puri V., Puri S. (2012). Serotonin and CGRP in Migraine. Ann. Neurosci. 19 (2), 88–94. 10.5214/ans.0972.7531.12190210 - DOI - PMC - PubMed

[6] Aggarwal M., Puri V., Puri S. (2012). Serotonin and CGRP in Migraine. Ann. Neurosci. 19 (2), 88–94. 10.5214/ans.0972.7531.12190210 - DOI - PMC - PubMed

[7] Agius A. M., Muscat R. (2019). Chronic Tension-type Facial Pain-A Pilot Study on HTTLPR Genetic Polymorphisms. Rhinology Online 2 (2), 125–133. 10.4193/rhinol/19.036 - DOI

[8] Agius A. M., Muscat R. (2019). Chronic Tension-type Facial Pain-A Pilot Study on HTTLPR Genetic Polymorphisms. Rhinology Online 2 (2), 125–133. 10.4193/rhinol/19.036 - DOI

[9] Ahn A. H., Basbaum A. I. (2005). Where Do Triptans Act in the Treatment of Migraine. Pain 115 (1-2), 1–4. 10.1016/j.pain.2005.03.008 - DOI - PMC - PubMed

[10] Ahn A. H., Basbaum A. I. (2005). Where Do Triptans Act in the Treatment of Migraine. Pain 115 (1-2), 1–4. 10.1016/j.pain.2005.03.008 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Pharmacogenetics in Primary Headache Disorders

Affiliations

Pharmacogenetics in Primary Headache Disorders

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Molecular Biology Databases

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

Related information

LinkOut - more resources

Full Text Sources

Molecular Biology Databases